Company intelligence / Profile preview

Alpha Cognition Inc.

Vancouver, British Columbia, Canadaalphacognition.com ↗

Ownership: Public · ACOG
Development stage: Commercial

Overview

Alpha Cognition received FDA approval for ZUNVEYL (benzgalantamine) in July 2024 for the treatment of mild-to-moderate Alzheimer's disease. The commercial launch occurred in March 2025, with the drug now available by prescription in pharmacies nationwide in three doses (5 mg, 10 mg, and 15 mg). The company has deployed a 32-person sales team focused on the $2 billion Long-Term-Care market.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

benzgalantamine

Approved

3 more assets in the full pipeline.

Request access →

Financials

Market cap: $147.9M
Total revenue: $6.1M
Enterprise value: $106.5M

Beyond the preview

Go deeper on Alpha Cognition Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha Cognition Inc..

Explore the full profile